Nisa Investment Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Nisa Investment Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,166	Closed	-$125K	–	2903
2023 Q1	$125K	Buy	1,166 +910	+355%	+$105K	﹤0.01%	1443
2022 Q4	$28K	Buy	256 +8	+3%	+$519	﹤0.01%	1961
2022 Q3	$13K	Buy	248 +22	+10%	+$1.01K	﹤0.01%	2155
2022 Q2	$6K	Sell	226 -604	-73%	-$17.5K	﹤0.01%	2263
2022 Q1	$31K	Buy	+830	New	+$32.8K	﹤0.01%	1967

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Nisa Investment Advisors's RXDX Position: Q2 2023 in Review

Nisa Investment Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,166 shares — an estimated $125K sold.

Nisa Investment Advisors first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $125K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Nisa Investment Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Nisa Investment Advisors sold 1,166 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $125K.
Nisa Investment Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Nisa Investment Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $125K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.